BioCentury | Oct 24, 2019
Preclinical News

Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more

...Louis identified three human antibodies that could serve as templates for universal flu vaccines targeting influenza virus neuraminidase...
...Sinai Merck & Co. Inc. Ionis Pharmaceuticals Inc. Baylor College of Medicine Broad Institute Mycobacterium tuberculosis secreted antigen 85-B (fbpB) (Ag85B) Influenza virus neuraminidase Interleukin-6...
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

...M2; NP - Influenza virus nucleoprotein; NS1 - Influenza virus non-structural protein 1; NA - Influenza virus neuraminidase...
...M2; NP - Influenza virus nucleoprotein; NS1 - Influenza virus non-structural protein 1; NA - Influenza virus neuraminidase...
...M2 NP - Influenza virus nucleoprotein NS1 - Influenza virus non-structural protein 1 NA - Influenza virus neuraminidase Winnie...
BioCentury | May 1, 2018
Company News

EC approves BioCryst's Alpivab for influenza

...on the EC approval. BioCryst was down $0.04 to $4.88 on Tuesday. Sandi Wong BioCryst Pharmaceuticals Inc. CSL Ltd. Influenza virus neuraminidase...
BioCentury | Mar 1, 2018
Clinical News

CHMP backs approval of BioCryst's Alpivab

...EU, Rapiacta - Japan, PeramiFlu - South Korea) (BCX-1812, RWJ-270201) Business: Infectious Sandi Wong Alpivab Peramivir BioCryst Pharmaceuticals Inc. Influenza virus neuraminidase...
BioCentury | Mar 21, 2013
Targets & Mechanisms

Trapping influenza neuraminidase

...The University of British Columbia have used a mechanism-based approach to design irreversible inhibitors of influenza virus neuraminidase...
BioCentury | Mar 14, 2013
Distillery Therapeutics

Indication: Infectious disease

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Influenza virus neuraminidase In vitro...
BioCentury | Sep 7, 1999
Tools & Techniques

Why Relenza was approved

...that contributed to Relenza's approval was the compound's novel mechanism of action - inhibition of influenza virus neuraminidase...
Items per page:
1 - 7 of 7